DJIA 16,805.41 127.51 0.76%
NASDAQ 4,483.72 30.92 0.69%
S&P 500 1,964.58 13.76 0.71%
market minute promo

1.36 -0.04 (-2.86%)

REAL-TIME: Last trade at


company name or ticker

Recent Quotes

NAVB $1.36 -2.86%
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $1.41
Previous Close $1.40
Daily Range $1.36 - $1.41
52-Week Range $1.11 - $2.26
Market Cap $204.9M
P/E Ratio -4.00
Dividend (Yield) $0.00 (0.0%)
Volume 267,720
Average Daily Volume 671,190
Current FY EPS -$0.24

Sector

Healthcare

Industry

Healthcare Information Services

Navidea Biopharmaceuticals, Inc. (NAVB) Description

Neoprobe Corporation is a biomedical company which is engaged in the development and commercialization of innovative surgical and diagnostic products that enhance patient care by meeting the critical decision making needs of physicians. Website: http://www.navidea.com/

News & Commentary Rss Feed

This Week in Biotech: Actions Speak Louder Than Words

Regulatory actions provided the impetus to big moves for these five biotech stocks.

Should You Buy Navidea Biopharmaceuticals?

Sector Update: Health Care Stocks Near Break-Even Marks; Navidea Wins Orphan Drug Designation for He

Sector Update: Health Care Stocks Near Break-Even Marks; Navidea Wins Orphan Drug Designation for Head, Neck Cancer Medication

Sector Update: Health Care

Should Navidea Biopharmaceuticals (NAVB) Be On Your Radar Now? - Tale of the Tape

Week In Review: DXY Receives $70 Million Investment From Tencent

Steve Brozak: Big-Picture Biotech Stocks Rule The Future

Navidea Biopharmaceuticals (NAVB) Q2 2014 Results - Earnings Call Webcast

Navidea Joins Essex Woodland's Rheumco, Will Develop Radiopharmaceuticals To Detect And Treat Arthri

Navidea Joins Essex Woodland's Rheumco, Will Develop Radiopharmaceuticals To Detect And Treat Arthritic Diseases

Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Investor Briefing on Sentinel Lymph Node

Navidea Biopharmaceuticals' (NAVB) CEO Michael Goldberg on Investor Briefing on Sentinel Lymph Node Biopsy in Head & Neck Cancers (Transcript)

Accuray Shows Continued Improvement - Analyst Blog

See More NAVB News...

NAVB's Top Competitors

NAVB $1.36 (-2.86%)
Current stock: NAVB
$0.00 (0.00%)
Current stock:
MDT $66.56 (1.45%)
Current stock: MDT
COV $89.64 (1.35%)
Current stock: COV